Socio-Economic Burden of Myasthenia Gravis: A Cost-of-Illness Study in Bulgaria

被引:16
作者
Ignatova, Valentina [1 ]
Kostadinov, Kostadin [2 ]
Vassileva, Evguenia [3 ,4 ]
Muradyan, Naira [3 ,4 ]
Stefanov, Georgi [5 ]
Iskrov, Georgi [2 ,5 ]
Stefanov, Rumen [2 ,5 ]
机构
[1] Natl Cardiol Hosp, Clin Neurol, Sofia, Bulgaria
[2] Med Univ Plovdiv, Fac Publ Hlth, Dept Social Med & Publ Hlth, Plovdiv, Bulgaria
[3] Univ Hosp Tsaritsa Yoanna ISUL, Clin Neurol, Sofia, Bulgaria
[4] Med Univ Sofia, Fac Med, Dept Neurol, Sofia, Bulgaria
[5] Inst Rare Dis, Plovdiv, Bulgaria
关键词
myasthenia gravis; cost-of-illness; socio-economic burden; burden of disease; societal costs; Bulgaria; CLINICAL-FEATURES; COMPLICATIONS; CRISIS;
D O I
10.3389/fpubh.2022.822909
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundMyasthenia gravis (MG) is a chronic autoimmune disorder, which is characterized by fatigable muscle weakness with frequent ocular signs and/or generalized muscle fatigue, and occasionally associated with thymoma. MG patients and their families face a significant socio-economic burden. This population is often experiencing unemployment, unwilling job transfers and decreased income. ObjectiveThis study aimed to estimate the annual costs from a societal perspective in a triple dimension of direct health care costs, direct non-health care costs (formal and informal care) and labor productivity losses in MG patients from Bulgaria, as well as to identify the main clinical and demographical cost drivers. MethodsA bottom-up, cross-sectional, cost-of-illness analysis of 54 adult MG patients was carried out in 2020. To collect data on demographic characteristics, health resource utilization, informal care and productivity losses, questionnaires were administered to and completed by patients. Results and ConclusionMedian annual costs of MG in Bulgaria were 4,047 EUR per patient. Direct costs slightly outweighed indirect costs, with drugs cost item having the biggest monetary impact. Despite the zero-inflated median, hospitalizations also influenced the direct costs by an estimated amount of 1,512 EUR in the 3rd quartile. Social services and professional caregiver costs were found to be almost missing, with the vast majority of patients reporting reliance on informal caregivers. Severe generalized disease, disease crises, and recurrent infections were confirmed as statistically significant cost driving factors. There were no severe generalized MG patients in the bottom quartile of the total costs distribution. It should be noted that in both cases of crises or infections, the overall increase in the total costs was mainly due to higher indirect costs observed. Reliance on family members as informal caregivers is routine among Bulgarian MG patients. This phenomenon is likely due to the lack of access to appropriate social services. Moreover, it is directly related with higher disease burden and significant inequalities. There is a need for further research on MG in Bulgaria in order to design targeted health policies that meet the needs and expectations of these patients.
引用
收藏
页数:8
相关论文
共 23 条
[1]   Myasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanisms [J].
Berrih-Aknin, Sonia ;
Le Panse, Rozen .
JOURNAL OF AUTOIMMUNITY, 2014, 52 :90-100
[2]   A systematic review of population based epidemiological studies in Myasthenia Gravis [J].
Carr, Aisling S. ;
Cardwell, Chris R. ;
McCarron, Peter O. ;
McConville, John .
BMC NEUROLOGY, 2010, 10
[3]  
Dimova A, 2018, HEALT SYST TRANSIT, V20, P1
[4]  
Drummond Michael F., 2005, Methods for the Economic Evaluation of Health Care Programmes, V3rd
[5]   Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology [J].
Fichtner, Miriam L. ;
Jiang, Ruoyi ;
Bourke, Aoibh ;
Nowak, Richard J. ;
O'Connor, Kevin C. .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[6]   Factors associated with acute exacerbations of myasthenia gravis [J].
Gummi, Rohit Reddy ;
Kukulka, Natalie Anna ;
Deroche, Chelsea B. ;
Govindarajan, Raghav .
MUSCLE & NERVE, 2019, 60 (06) :693-699
[7]   Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion [J].
Iskrov, Georgi ;
Dermendzhiev, Svetlan ;
Miteva-Katrandzhieva, Tsonka ;
Stefanov, Rumen .
FRONTIERS IN PHARMACOLOGY, 2016, 7
[8]  
Ivanov Z., 2020, REDK BOLES LEK SIRAC, V11, P24, DOI [10.36865/2020.v11i4.125, DOI 10.36865/2020.V11I4.125]
[9]   Myasthenia gravis - Recommendations for clinical research standards [J].
Jaretzki, A ;
Barohn, RJ ;
Ernstoff, RM ;
Kaminski, HJ ;
Keesey, JC ;
Penn, AS ;
Sanders, DB .
NEUROLOGY, 2000, 55 (01) :16-23
[10]   Predictors of outcome of myasthenic crisis [J].
Kalita, J. ;
Kohat, A. K. ;
Misra, U. K. .
NEUROLOGICAL SCIENCES, 2014, 35 (07) :1109-1114